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Abstract
Introduction: Evaluation of pharmacotherapy during inten-
sive care treatment is commonly based on subjective, inter-
mittent interpretations of physiological parameters. Real-
time visualization and analysis may improve drug effect 
evaluation. We aimed to evaluate the effects of the respira-
tory stimulant doxapram objectively in preterm infants us-
ing continuous physiological parameters. Methods: In this 
longitudinal observational study, preterm infants who re-
ceived doxapram therapy were eligible for inclusion. Physi-
ological data (1 Hz) were used to assess respiration and to 
evaluate therapy effects. The oxygen saturation (SpO2)/frac-
tion of inspired oxygen (FiO2) ratio and the area under the 
89% SpO2 curve (duration × saturation depth below target) 
were calculated as measures of hypoxemia. Regression anal-
yses were performed in 1-h timeframes to discriminate ther-
apy failure (intubation or death) from success (no intuba-
tion). Results: Monitor data of 61 patients with a median 
postmenstrual age (PMA) at doxapram initiation of 28.7 (IQR 
27.6–30.0) weeks were available. The success rate of doxa-
pram therapy was 56%. Doxapram pharmacodynamics were 
reflected in an increased SpO2 and SpO2/FiO2 ratio as well as 
a decrease in episodes with saturations below target (SpO2 
< 89%). The SpO2/FiO2 ratio, corrected for PMA and mechan-
ical ventilation before therapy start, discriminated best be-
tween therapy failure and success (highest AUC ROC of 0.83). 
Conclusion: The use of continuous physiological monitor 
data enables objective and detailed interpretation of doxa-
pram in preterm infants. The SpO2/FiO2 ratio is the best pre-
dictive parameter for therapy failure or success. Further im-
plementation of real-time data analysis and treatment algo-
rithms would provide new opportunities to treat newborns.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
It is difficult to evaluate clinical effects of pharmaco-
therapy in preterm infants with continuously changing 
pharmacokinetics and pharmacodynamics. Doxapram is 
used off-label as a second-line treatment for persistent 
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apnea of prematurity next to caffeine and noninvasive 
ventilation. It stimulates the respiratory drive through the 
brainstem respiratory center and the peripheral carotid 
and aortic chemoreceptors [1]. Doxapram is prescribed 
to avoid hypoxemic periods and to reduce the need for 
invasive mechanical ventilation (MV) [2]. Hypoxemic 
periods should be avoided as they are associated with an 
increased risk for late death or disability [3]. The occur-
rence of apneas is evaluated inconsistently based on the 
impression that nurses get from bedside alarm signals [4]. 
Additionally, only snapshots of bedside monitor data are 
used to assess a patient’s condition. Clinical decision-
making is thus commonly based on these subjective, 
snapshot interpretations, and a vast amount of potential-
ly relevant information is discarded. 
Storing, recalling, and analyses of per-second available 
physiological data may provide clinicians with informa-
tion on the trends in a patient’s condition. Real-time anal-
ysis of this trend data can extract detailed information on 
important clinical changes and may predict therapy effect 
and outcome. The effectiveness of therapy may be in-
creased and toxicity reduced. A small pilot study already 
showed that monitor data could potentially be used to 
evaluate doxapram therapy [5]. 
The aim of this study was to use doxapram therapy as 
a proof of principle to demonstrate the use of monitor 
data for the objective and continuous evaluation of respi-
ration and drug effects in preterm infants.
Materials and Methods
In this longitudinal observational study, prospectively collect-
ed physiological data were analyzed. Eligible for inclusion were 
preterm infants with a birth weight < 1,500 g who received doxa-
pram therapy between December 2013 and June 2017 at the neo-
natal intensive care unit (NICU) of Sophia Children’s Hospital 
(Rotterdam, The Netherlands). Patients of the earlier conducted 
pilot study were part of this population. The local ethics review 
board granted a waiver from approval according to the Medical 
Research Involving Human Subjects Act (WMO) in the Nether-
lands (MEC-2018-1106).
Baseline characteristics were collected from the electronic 
medical records (HiX, Chipsoft, Amsterdam, The Netherlands). 
Ventilation mode and fraction of inspired oxygen (FiO2) data were 
collected from the electronic patient data management system (Pi-
cis Clinical Solutions, Inc., Wakefield, MA, USA). Physiological 
data – arterial oxygen saturation (SpO2), respiratory rate (RR), and 
heart rate (HR) – were continuously and automatically recorded 
(1 Hz) from bedside monitors (Dräger, Lübeck, Germany). The 
SpO2 was measured with pulse oximeters (Masimo Corporation, 
Irvine, CA, USA), and HR was derived from the electrocardio-
gram. Data were analyzed from 1 week before therapy start until 2 
weeks after therapy start or therapy stop.
Doxapram was administered if apnea of prematurity persisted 
under optimized caffeine treatment and noninvasive ventilation. 
The local protocol proposed a loading dose of 2.5 mg/kg in 15 min, 
on indication of the attending physician, and a continuous main-
tenance dose of 2.0 mg/kg/h by intravenous infusion or gastroin-
testinal administration. Clinicians assessed doxapram effective-
ness by the occurrence of apneas and bradycardias, and alarm sig-
nals according to the local standards for SpO2, RR, and HR. The 
alarms were set to indicate SpO2 below 89% or over 95%, HR below 
100 or over 200 bpm, and a respiratory pause of 20 s or longer. The 
maintenance dose was gradually reduced or stopped on clinical 
indication, or when MV was required. MV was not administered 
during doxapram therapy. The local criteria to start MV included 
persisting or severe apnea, increased oxygen needs or severe de-
saturations. Therapy success was defined as no MV requirement 
at therapy stop, and therapy failure was defined as death or MV 
requirement at therapy stop. A new doxapram course was defined 
as therapy restart at least 24 h after stop of the previous course.
Data were filtered for measurements that were marked as in-
valid by the patient monitoring system. Zero values were removed 
from the analysis as they also could indicate a disconnected sensor. 
The number and duration of episodes with saturations below an 
SpO2 limit of 89%, the local lower alarm limit, were derived from 
the SpO2. The area under the 89% SpO2 limit curve (SpO2 AUC) 
was calculated by multiplying the time by the depth under the lim-
it per second. All data were preprocessed using LabVIEW (Na-
tional Instruments, Austin, TX, USA). The SpO2/FiO2 ratio was 
calculated per second where both SpO2 and FiO2 measurements 
were available. 
The statistical analyses were performed using R software (ver-
sion 3.5.3, Inc., Boston, MA, USA) and differences were consid-
ered significant at p < 0.05. Baseline characteristics were analyzed 
using the Wilcoxon rank sum test, χ2 test, or Fisher’s exact test. The 
sample was analyzed as a whole and in subgroups for therapy fail-
ure and success. The physiological data were described by median 
(IQR) per hour. Differences in physiological data between therapy 
failure and success at 12 and 1 h before, and 4 and 12 h after doxa-
pram start were tested using the Wilcoxon rank sum test. Missing 
data points were assumed to be completely at random and were 
therefore excluded from the analysis.
Logistic regression models were fitted for each 1-h timeframe 
in the 48 h around therapy start with the SpO2/FiO2 ratio as inde-
pendent variable. Only patients who had received doxapram for 
24 h or more were included in the analysis. The same approach was 
applied with models including patient characteristics, the post-
menstrual age (PMA) at therapy start, and MV in the 24 h before 
therapy start, and with models including both the SpO2/FiO2 ratio 
and the patient characteristics. The area under the receiver operat-
ing characteristic curve (AUC ROC) was calculated for each of the 
models. 
Linear mixed-effects models were computed for each physio-
logical parameter (R package “nlme”, version 3.1-137). We al-
lowed for a nonlinear effect of time in the fixed-effects part, using 
natural splines concentrated around therapy start. In the random-
effect part we included random intercepts and splines. Differenc-
es within each of the parameters before and after therapy start 
were tested per 4-h timeframe using the predicted data from the 
mixed models. The degree of change was visualized with the in-
tensity of colors in matrix plots, significant differences were 






During the study period, 121 patients received doxa-
pram therapy. We excluded 5 patients (4%) due to the 
following reasons: therapy data missing (n = 3), trans-
ferred to another hospital (n = 1), birth weight > 1,500 g 
(n = 1). Monitor data were successfully collected for 
61/116 patients (53%). No statistically significant differ-
ences were found between patients with and without 
available monitor data (Table 1). A total of 23,640 h (92%; 
82,776,281 data points) of data were available for analysis. 
The overall success rate was 56%. The gestational age 
in patients with therapy success (26.3 [25.4–27.3] weeks) 
was higher than in patients with therapy failure (25.3 
[24.5–26.3] weeks; p < 0.01). The postnatal age at initia-
tion (p < 0.01) – and consequently also the PMA at initia-
tion (p < 0.01) – was lower in patients with therapy failure 
(Table 2). Patients with therapy failure had a longer NICU 
stay (p = 0.02), were treated shorter (p < 0.01), and were 
more often on MV during the 24 h before start (p < 0.01). 
None of the patients received high-flow or MV at start of 
doxapram.
Table 1. Baseline characteristics of the study population
Characteristics Patients without 
monitor data (n = 55)
Patients with 
monitor data (n = 61)
p value*
Gestational age, weeks 26.0 (24.9–27.1) 26.1 (24.9–26.7) 0.57
Birth weight, g 800 (645–1,000) 750 (650–910) 0.44
Multiple birth (yes) 19 (35) 17 (28) 0.57
Male gender 33 (60) 42 (69) 0.42
Postnatal agea, days 19.9 (13.4–26.0) 20.9 (14.1–25.2) 0.72
Postmenstrual agea, weeks 29.0 (27.5–30.8) 28.7 (27.6–30.0) 0.49
Admission period, days 69 (44–84) 66 (51–97) 0.33
Mortality (yes) 8 (15) 7 (11) 0.78 
Data are presented as median (IQR) or as n (%). a Age at doxapram initiation. * p value from the Wilcoxon 
rank sum test, Fisher’s exact test, and χ2 test.
Table 2. Patient characteristics classified in therapy success or therapy failure





Gestational age, weeks 26.3 (25.4–27.3) 25.3 (24.5–26.3) <0.01
Birth weight, g 820 (650–985) 730 (648–868) 0.10
Multiple birth (yes) 22 (34) 14 (27) 0.55
Male gender 37 (57) 38 (73) 0.11
Postnatal agea, days 21.9 (16.8–29.9) 16.6 (12.7–22.8) <0.01
Postmenstrual agea, weeks 29.9 (28.2–31.3) 27.7 (27.1–28.7) <0.01
Admission period, days 58.5 (45.2–78.5) 76.0 (55.5–92.9) 0.03
Mortality (yes) 1 (2) 14 (27) <0.01
Duration of therapy, days 9.9 (4.7–17.6) 1.8 (0.6–5.0) <0.01
Ventilation ≤24 h before start (yes) 16 (25) 30 (58) <0.01
Number of doxapram courses <0.01
1 course 53 (82) 25 (48)
2 courses 10 (15) 15 (29)
3 courses 1 (2) 10 (19)
4 courses 1 (2) 2 (4)
Data are presented as median (IQR) or as n (%). The patients are classified based on the therapy outcome of 
the first doxapram course. a Age at doxapram initiation. * p value from the Wilcoxon rank sum test, Fisher’s ex-
act test, and χ2 test.
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Fig. 1. Trends of patients with available 
monitor data (n = 61) divided into groups 
with therapy failure and success in the arte-
rial oxygen saturation (SpO2), fraction of 
inspired oxygen (FiO2), SpO2/FiO2 ratio, 
number and duration of episodes with sat-
urations below the SpO2 limit of 89%, and 
the area under the curve below the SpO2 
limit of 89% (a). Data were derived from 
82,776,281 unique measurements and vi-
sualized from 1 week before doxapram 
start until 2 weeks after doxapram start, 
and in a 48-h timeframe around doxapram 
start. The difference between the groups 
with therapy failure and success was tested 
at 12 and 1 h before doxapram, and 4 and 
12 h after doxapram start. Significant dif-
ferences are visualized in the 48-h time-
frame graphs. Data obtained after therapy 
stop within the 2 weeks’ study period were 
excluded from the analyses. The number of 
patients in the analyses, therefore, decreas-
es during the study period. The total 
amount of patients in the analyses is pre-
sented per hour (b). Doxapram start is in-





The largest differences in the physiological data were 
seen in the first hours after therapy start (Fig. 1). Over-
all, the duration of episodes with saturations below tar-
get had decreased from 14 (10–20) to 3 (0–6) min/h 
(79%), the number of episodes with saturations below 
target from 22 (15–28) to 7 (2–17) (69%), the AUC 
SpO2 from 2.0%/s (1.3–3.5) to 0.2%/s (0.0–0.4) (90%), 
and the FiO2 from 30% (26–40) to 27% (24–37) (10%) 
between 1 h before doxapram start and 4 h after start. 
The SpO2/FiO2 ratio had increased from 3.0 (2.2–3.6) 
to 3.5 (2.5–4.1) (17%) and the SpO2 from 93% (88–96) 
to 95% (93–97) (2%). The HR increased from 165 (156–
175) to 168 (160–177) bpm (2%) and the RR decreased 
from 51 (34–68) to 49 (35–65) bpm (4%; Fig. 2). The 
number of patients in the analysis was visualized per 
hour (Fig. 1b). At 1 h before and 4 and 12 h after doxa-
pram start, the FiO2 and SpO2/FiO2 ratio differed sig-
nificantly between patients with therapy failure and 
success (p < 0.01).
The results of the mixed-effects models are provided in 
online supplementary Figures S1 and S2 (for all online sup-
pl. material, see www.karger.com/doi/10.1159/000509269). 
The predicted data of the mixed models showed similar 
trends in the physiological parameters when compared to 
the raw data. 
The SpO2/FiO2 ratio trend in patients with therapy 
success differed from patients with therapy failure 
(Fig. 1a). The SpO2/FiO2 ratio had a steeper decrease be-
fore therapy start in patients with therapy failure than in 
patients with therapy success. The SpO2/FiO2 ratio in-
creased after start in the group with therapy success and 
remained constant in the group with therapy failure. This 
trend in the SpO2/FiO2 ratio was still observed in both 
groups after 2 weeks (Fig. 1a).
Fifty-four patients received doxapram therapy for 
24 h or more. Figure 3b shows the discriminative ability 
of the SpO2/FiO2 ratio (Model 1), the PMA at doxapram 
administration and MV within 24 h before start (Model 
2), and the combination of these 2 (Model 3). The ability 
to discriminate between therapy failure and success ac-
cording to the hourly AUC ROC varied between 0.63 and 
0.77 for Model 1, was 0.77 for Model 2, and varied be-
tween 0.77 and 0.83 for Model 3.
Discussion
This study used high-density physiological data to evalu-
ate pharmacotherapy in preterm infants, and to predict re-
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Fig. 2. The trends of the heart rate (bpm) and the respiratory rate (bpm) from 1 week before therapy start until 
2 weeks after therapy start or therapy stop. Data obtained after therapy stop within the 2 weeks’ study period were 
excluded from the analyses. The number of patients in the analyses can be found in Figure 1b. Doxapram start is 
indicated by the vertical red line at time = 0.
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increased SpO2 and SpO2/FiO2 ratio levels, lower number 
and shorter duration of episodes with saturations below tar-
get, as well as lower SpO2 AUC and FiO2 levels. The SpO2/
FiO2 ratio, corrected for PMA and MV during the 24 h be-
fore therapy start, was found to be discriminative for ther-
apy outcome. These analyses of monitor data can provide 
an objective assessment of pharmacotherapy effects that is 
superior to the “snapshots” used in current clinical practice. 
The success rate of doxapram is comparable to previ-
ous studies [2, 6]. Doxapram can be effective for avoiding 
hypoxia and MV if administered to doxapram responders 
with the right indication. Trend visualization of physio-
logical data could improve assessment of the respiratory 
status before starting therapy, avoiding unnecessary treat-
ment. Real-time analysis of physiological data enables de-
tection of early-onset patterns, probability assessments, 
and prediction of certain events over time. Applications of 
these analyses served to predict imminent critical deterio-
ration [7] and cardiac arrest in the pediatric ICU [8]. HR 
characteristics have been used for early detection of late-
onset neonatal sepsis, with lower mortality as a result [9].
In preterm infants, SpO2 needs to be strictly managed 
because of the risks of impaired neurodevelopment due 
to hypoxemia and retinopathy of prematurity due to hy-
peroxemia [3, 10–14]. Integration of SpO2 and FiO2 gives 
insight into the respiratory status of the patient as it ac-
counts for the supplied oxygen level. The SpO2/FiO2 ratio 
was found to be a reliable marker for acute lung injury 
and acute respiratory distress syndrome in adults and 
children [15–17]. The SpO2/FiO2 ratio in preterm infants 
is inversely correlated with the gestational age at 36 weeks’ 
PMA, and is lower in infants with worse respiratory dis-
ease patterns [18]. In contrast to the oxygen saturation 
index (OSI; [FiO2 × mean airway pressure]/SpO2), the 
SpO2/FiO2 ratio does not include the mean airway pres-
sure. The OSI has been validated only in invasively venti-
lated patients in the first days of life [19–21] and none of 
the patients in this study received MV around doxapram 
start or during doxapram therapy. Integration of nonin-
vasive pressure support could further improve therapy, 
although it is known to be an unreliable measure for the 
mean airway pressure in the lungs. 
Patients with therapy failure more often had MV 
during the 24 h before therapy start (p < 0.01). This 
could indicate extubation failure, resulting in higher 
need for respiratory support. MV was probably started 
in patients who had less capacity to overcome apneas. 
Apneas could result in hypoxic episodes more often, 
and the stimulatory effect of doxapram could be absent 
during hypoxia [22]. Although speculative, this could 
explain why doxapram was less beneficial in patients 
who needed MV just before therapy start. In ventilated 
patients, the SpO2/FiO2 ratio can be equal to that in 
noninvasively or nonventilated patients, thus conceal-
ing possibly worse hypoxemic events. The SpO2/FiO2 
ratio in invasively ventilated patients is likely an over-
estimation of the respiratory status. This could explain 
the increasing discriminative ability before therapy 
start when patient characteristics, including MV, were 
added to the model.
The most important contribution of this study is the 
incentive for bedside trend visualization and more con-





















Fig. 3. The discriminative ability of the ox-
ygen saturation (SpO2)/fraction of inspired 
oxygen (FiO2) ratio for therapy outcome. 
Doxapram start is indicated by the vertical 
red line at time = 0. Models included data 
based on patients with a therapy duration 
of 24 h or more. Patients with a therapy du-
ration below 24 h (n = 7) were excluded 
from these analyses. This graph shows the 
results of the hourly discriminative models 
for therapy success and failure, using the 
area under the ROC curve. The first groups 
of models included the SpO2/FiO2 ratio 
(Model 1). The second group included the 
patient characteristics: postmenstrual age 
at doxapram initiation and invasive venti-
lation during the 24 h before therapy start 
(Model 2). The third group included both 






tinuous and objective pharmacotherapeutic evaluation in 
respiratory unstable patients. The SpO2/FiO2 ratio and 
episodes with a saturation below target can provide high-
ly relevant information to clinicians on indication and 
individual dose evaluation of pharmacotherapy. We de-
termined an acceptable to excellent discriminative ability 
for therapy outcome using physiological data [23]. The 
next step would be to calculate individualized risk index-
es to predict therapy failure. Determination of cutoff val-
ues indicative of clinical conditions can validate param-
eters for objective decision-making. Such use of physio-
logical data could be applied to other neonatal treatments, 
such as evaluation of caffeine effectiveness and safety 
[24], antibiotic dosing [25], and measurement of respira-
tory depression after morphine administration [26].
Several limitations of the study need to be addressed. 
First, the population at the NICU is heterogeneous, mak-
ing it difficult to define a valid control group. In this 
study, each patient serves as his own control. The breath-
ing center, however, matures over time, causing less ap-
nea and related desaturations over time. We therefore 
corrected for the PMA at doxapram start in the discrimi-
nation of therapy outcome. Second, therapy failure was 
defined as MV requirement. The decision to start MV was 
made by the clinical team as consensus about respiratory 
insufficiency, and objective intubation criteria are lacking 
in neonatal treatment. Scores to assess the apnea severity 
have been suggested before but have not been validated 
in clinical practice [27]. This is a limitation, although it 
reflects the current standard of care. 
In the near future, patient monitoring will inevitably 
contain real-time algorithms derived from continuous 
physiological data. Clinicians will be provided with infor-
mation that in its raw form is too complex to be inter-
preted by the human brain. Translation of our findings to 
the bedside enables objective effect monitoring over time, 
and objective determination of respiratory failure. Objec-
tive and continuous monitoring enhances clinical deci-
sion-making, and therapy can be adjusted based on the 
alterations of a patient’s condition. This individualized 
treatment strategy is likely to lead to higher drug effectiv-
ity and fewer side effects compared to current clinical 
practice.
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